Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.

@article{Gallmeier2011InhibitionOA,
  title={Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.},
  author={Eike Gallmeier and Patrick C. Hermann and M M{\"u}ller and Juan G Machado and Andreas Ziesch and Enrico Narciso De Toni and Andreas Palagyi and Christian Eisen and J. Ellwart and Jos{\'e} Rivera and Bel{\'e}n Rubio-Viqueira and Maartje Hidalgo and Fred Bunz and Burkhard J. G{\"o}ke and Christopher Heeschen},
  journal={Stem cells},
  year={2011},
  volume={29 3},
  pages={418-29}
}
The identification of novel approaches to specifically target the DNA-damage checkpoint response in chemotherapy-resistant cancer stem cells (CSC) of solid tumors has recently attracted great interest. We show here in colon cancer cell lines and primary colon cancer cells that inhibition of checkpoint-modulating phosphoinositide 3-kinase-related (PIK) kinases preferentially depletes the chemoresistant and exclusively tumorigenic CD133(+) cell fraction. We observed a time- and dose-dependent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…